DDrare: Database of Drug Development for Rare Diseases

301. 黄斑ジストロフィー
［臨床試験数：41，薬物数：47（DrugBank：12），標的遺伝子数：12，標的パスウェイ数：66］

Searched query = "Macular dystrophy", "Best disease", "Stargardt disease", "Cone dystrophy", "Cone rod dystrophy", "X-linked juvenile retinoschisis", "Central areolar choroidal dystrophy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 4-Methylpyrazole; 4-methylpyrazole; ACU-4429; ALK-001; ALK-001 (No generic name); ARC1905; ARC1905 20 MG/ML; Avacincaptad pegol; DAC; DHA; Device: Medmont Darl Adapted Chromatic (DAC); Device: MonCvONE electrophysiology; Device: RetMap, RM Electrode; Diagnostic Test: Ocular Coherence Tomography-Angiography (OCT-A); Docosahexaenoic Acid (DHA) Dietary Supplement; Docosahexaenoic acid; EMIXUSTAT HYDROCHLORIDE (ACU-4429); EPA; Emixustat; Emixustat hydrochloride; HESC-RPE; Interferon Gamma; Interferon gamma-1b; Lentiviral vector containing ABCA4 gene; Long term follow up in all patients who received SAR422459 in previous study TDU13583; MA09-hRPE; Madeos; Metformin; Metformin hydrochloride; Other: Sham; Other: Standard of Care Sildenafil; Other: Visual Acuity (VA); Other: saline; Over the counter DHA/EPA dietary supplementation; Ranibizumab; Ranibizumab injection (0.5 mg); SAR422459; SORAPRAZAN; STG-001; Saffron supplementation; Sildenafil; Soraprazan; StarGen; Stem/progenitor cells transplantation; VA; Vett Lentiviral con gene ABCA4; Zimura

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00420602 (ClinicalTrials.gov)	September 21, 2007	10/1/2007	DHA Supplementation in Patients With STGD3	Clinical Interventions Against Stargardt Macular Dystrophy: DHA Supplementation in Patients With STGD3	Dominantly Inherited Stargardt's Disease (STGD3)	Dietary Supplement: Over the counter DHA/EPA dietary supplementation	University of Utah	NULL	Completed	18 Years	105 Years	All	11	N/A	United States
2	NCT00060749 (ClinicalTrials.gov)	May 5, 2003	9/5/2003	Effect of DHA Supplements on Macular Function in Patients With Stargardt Macular Dystrophy and Stargardt-like Macular Dystrophy	Investigation of the Effect of Dietary Docosahexaenoic Acid (DHA) Supplementation on Macular Function in Subjects With Autosomal Dominant Stargardt-Like and Autosomal Recessive Stargardt Macular Dystrophy	Macular Degeneration	Drug: Docosahexaenoic Acid (DHA) Dietary Supplement	National Eye Institute (NEI)	NULL	Completed	N/A	N/A	All	22	Phase 1	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00420602
(ClinicalTrials.gov)

September 21, 2007

10/1/2007

DHA Supplementation in Patients With STGD3

Clinical Interventions Against Stargardt Macular Dystrophy: DHA Supplementation in Patients With STGD3

Dominantly Inherited Stargardt's Disease (STGD3)

Dietary Supplement: Over the counter DHA/EPA dietary supplementation

University of Utah

NULL

Completed

18 Years

105 Years

All

N/A

United States

NCT00060749
(ClinicalTrials.gov)

May 5, 2003

9/5/2003

Effect of DHA Supplements on Macular Function in Patients With Stargardt Macular Dystrophy and Stargardt-like Macular Dystrophy

Investigation of the Effect of Dietary Docosahexaenoic Acid (DHA) Supplementation on Macular Function in Subjects With Autosomal Dominant Stargardt-Like and Autosomal Recessive Stargardt Macular Dystrophy

Macular Degeneration

Drug: Docosahexaenoic Acid (DHA) Dietary Supplement

National Eye Institute (NEI)

NULL

Completed

N/A

All

Phase 1

United States